Dr. Katherine Harris is Chief Development Officer at Rondo Therapeutics, where she leads IND-enabling activities and oversees preclinical drug development from candidate nomination through IND submission. She is a biopharma executive and board director with deep expertise in antibody therapeutics, guiding programs from discovery through translational decision-making and into the clinic.
Dr. Harris is President and a member of the Board of Directors of The Antibody Society, where she helps advance the global antibody community through scientific exchange, education, and collaboration across industry, academia, and medicine.
Previously, Dr. Harris held senior leadership roles at TeneoBio and Amgen, where she built and led oncology research organizations, shaped antibody discovery platforms, and provided strategic and scientific direction for antibody therapeutics programs. At TeneoBio, her leadership contributed to four IND approvals in under six years, and following the company’s acquisition, she led integration of the TeneoBio portfolio and platform into Amgen’s oncology R&D organization while serving as site head of the Amgen Newark Research Facility.
Dr. Harris brings a systems-level approach to therapeutic development, emphasizing clarity, alignment, and the decisions that ultimately determine clinical success. She holds a Ph.D. in Molecular and Cell Biology from University of California, Berkeley and has authored multiple peer-reviewed publications and issued patents.
